Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Biocidium Biopharmaceuticals General Information
Biocidium has multiple candidates in preclinical and early clinical stages. Their antibiotics have shown 99.99%+ efficacy against 90%+ of bacteria listed by the CDC, FDA, and ESKAPE Program as drug-resistant or multi-drug resistant. Their antifungals have demonstrated efficacy against 100% of fungal infections listed by both the CDC and FDA as drug-resistant and multi-drug resistant fungi.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Chatsworth, California
United States
United States
Drug Pipeline
BCM-0184
Pre-clinicalKey Partnerships
Biocidium Biopharmaceuticals Funding
No funding data available
To view Biocidium Biopharmaceuticals's complete valuation and funding history, request access »